YUTIQ
Clinical safety rating: caution
Comprehensive clinical and safety monograph for YUTIQ (YUTIQ).
YUTIQ (fluocinolone acetonide intravitreal implant) is a corticosteroid that binds to glucocorticoid receptors, leading to inhibition of phospholipase A2, suppression of arachidonic acid release, and downregulation of pro-inflammatory mediators such as prostaglandins, leukotrienes, and cytokines. This reduces inflammation and vascular permeability in the eye.
| Metabolism | Fluocinolone acetonide is metabolized primarily in the liver via cytochrome P450 3A4 (CYP3A4) to inactive metabolites. Intravitreal fluocinolone acetonide is released slowly and undergoes local metabolism; systemic absorption is minimal. |
| Excretion | Primarily hepatic/biliary; fecal excretion is the major route. Renal excretion of fluocinolone acetonide and metabolites accounts for <10%. |
| Half-life | Approximately 36 months (3 years) from the intravitreal implant; reflects sustained release from the non-biodegradable implant matrix. |
| Protein binding | Approximately 90% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Following systemic absorption, Vd is approximately 99 L (1.4 L/kg for a 70 kg adult), indicating extensive tissue distribution. |
| Bioavailability | Intravitreal administration results in local ocular availability; systemic bioavailability is negligible (<1% of administered dose). |
| Onset of Action | Therapeutic effect on inflammation typically observed within 2 weeks following intravitreal implantation. |
| Duration of Action | Up to 36 months (3 years) due to continuous release of fluocinolone acetonide from the implant. |
| Molecular Weight | 452.5 |
0.18 mg fluocinolone acetonide intravitreal implant (single administration) releasing 0.2 mcg/day over 36 months.
| Dosage form | IMPLANT |
| Renal impairment | No dose adjustment required; pharmacokinetics unaffected by renal impairment. |
| Liver impairment | No dose adjustment required; not studied in hepatic impairment. |
| Pediatric use | Safety and efficacy not established in pediatric patients. |
| Geriatric use | No specific dose adjustment; use caution due to higher susceptibility to corticosteroid effects (e.g., intraocular pressure elevation, cataract progression). |
| 1st trimester | Contraindicated due to risk of fetal harm; intravitreal fluocinolone acetonide may cause adrenal suppression and other corticosteroid effects. Use only if potential benefit outweighs risk. |
| 2nd trimester | Contraindicated; limited data but corticosteroid exposure associated with orofacial clefts and growth restriction. Use only if clearly needed. |
| 3rd trimester | Contraindicated; potential for neonatal adrenal suppression if exposed near term. Avoid unless essential. |
Clinical note
Comprehensive clinical and safety monograph for YUTIQ (YUTIQ).
| Placental transfer | Corticosteroids cross the placenta; fluocinolone acetonide is a potent corticosteroid. Degree of transfer is significant based on molecular weight and lipophilicity. |
| Breastfeeding | Not recommended during breastfeeding. Fluocinolone acetonide is excreted in human milk; risk of growth suppression and adrenal suppression in the infant. A decision should be made to discontinue nursing or discontinue the drug. |
■ FDA Black Box Warning
None
| Serious Effects |
Active ocular or periocular infections (including viral, fungal, bacterial, or mycobacterial)Advanced glaucoma that is not adequately controlled with medicationHypersensitivity to fluocinolone acetonide or any component of the implant
| Precautions | Increased intraocular pressure (IOP) requiring monitoring and possible glaucoma surgery; cataract formation; endophthalmitis (sterile and infectious); retinal detachment; vitreous hemorrhage; corneal edema; exacerbation of ocular infections; corticosteroid-induced systemic effects (rare with intravitreal use). |
| Food/Dietary | No known food interactions. |
Loading safety data…
| Lactation Rating | L5 (Contraindicated) |
| Teratogenic Risk | YUTIQ (fluocinolone acetonide intravitreal implant) is contraindicated in pregnancy due to proven teratogenicity in animal studies. In rats and rabbits, systemic corticosteroids including fluocinolone acetonide produced fetal resorptions, cleft palate, and delayed ossification at doses below the human exposure level. There are no adequate human studies. The implant releases corticosteroid over 36 months, resulting in sustained systemic exposure. First trimester exposure carries highest risk for structural anomalies; second and third trimester use may impair fetal growth and adrenal function. |
| Fetal Monitoring | If YUTIQ is inadvertently used in pregnancy, monitor fetal growth with serial ultrasound assessments due to risk of intrauterine growth restriction (IUGR). Assess amniotic fluid volume. After delivery, evaluate the neonate for signs of adrenal insufficiency (e.g., hypoglycemia, hypotension, poor feeding). Maternal monitoring includes blood pressure, blood glucose, and signs of infection due to corticosteroid immunosuppression. |
| Fertility Effects | In animal studies, high doses of systemic corticosteroids impaired fertility in rats, characterized by prolonged estrous cycles and reduced implantation. In humans, chronic corticosteroid use can cause hypothalamic-pituitary-adrenal (HPA) axis suppression, potentially altering menstrual cycles and ovulation. Reversible infertility may occur. YUTIQ's sustained corticosteroid release could similarly affect fertility. Advise patients of possible temporary impairment. |
| Clinical Pearls |
| Intravitreal injection of YUTIQ (fluocinolone acetonide) provides sustained release for up to 36 months. Monitor for elevated intraocular pressure (IOP) and cataract formation. Use with caution in patients with glaucoma or history of ocular hypertension. Screen for active ocular infections prior to administration. |
| Patient Advice | Do not rub or press on the treated eye. · Report any sudden changes in vision, eye pain, or redness immediately. · You may need regular eye exams to check eye pressure and for cataracts. · Avoid swimming or using hot tubs for at least one week after injection. · Inform all healthcare providers that you have received this implant. |